We are developing a potential vaccine based on our proprietary mRNA technology to induce immunity and prevent COVID-19 infections in response to the growing global health threat. In order to accelerate the rapid development of our product candidate BNT162 we initiated the global development program Lightspeed. The program leverages
BioNTech’s proprietary mRNA platforms for infectious diseases,
its fully-owned GMP manufacturing infrastructure for mRNA vaccine production,
its global clinical development capabilities, and
collaborations with Pfizer and Fosun Pharma
BioNTech also photo